Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-28

Clinical Trial Update: Effect of a CCK-1R Agonist on Food Intake in Humans [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a CCK-1R agonist for food intake in bulimia; the study was terminated and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CCK-1R agonist

Snippet

Sponsor: St. Luke's-Roosevelt Hospital Center | Conditions: Bulimia | Phase 2 | Status: TERMINATED | Results posted: 2017-04-28